Insulet reported $584.4M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Abbott USD 4.05B 1.05B Sep/2026
Align Technology USD 1.1B 42.76M Jun/2026
AtriCure USD 187.03M 19.24M Sep/2026
Baxter International USD 1.98B 175M Sep/2026
Becton, Dickinson and Co. USD 725M 17M Sep/2026
Boston Scientific USD 609M 70M Sep/2026
Cardinal Health USD 5.26B 408M Sep/2026
Cooper Companies USD 138.8M 13.9M Mar/2026
Dexcom USD 961.4M 143.6M Sep/2026
Edwards Lifesciences USD 3.11B 210.8M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Globus Medical USD 441.27M 66.47M Sep/2026
ICU Medical USD 298.3M 9.97M Jun/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 584.4M 49.5M Sep/2026
Integra LifeSciences USD 252.26M 37.85M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Medtronic USD 1.69B 258M Jun/2026
Merit Medical Systems USD 503.55M 54.85M Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Solventum Corp USD 451M 48M Sep/2026
Stryker USD 3.27B 120M Sep/2026
Tandem Diabetes Care USD 72.84M 10.02M Sep/2026
Teleflex USD 430.46M 130.31M Sep/2026
West Pharmaceutical Services USD 464.1M 28.3M Sep/2026
Zimmer Biomet Holdings USD 399.9M 10.1M Sep/2026